

Alessandro Tomelleri

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5000339/publications.pdf>

Version: 2024-02-01

97
papers

2,480
citations

331538

21
h-index

214721

47
g-index

98
all docs

98
docs citations

98
times ranked

5138
citing authors

#	ARTICLE	IF	CITATIONS
1	Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. <i>Lancet Rheumatology</i> , The, 2020, 2, e325-e331.	2.2	808
2	Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. <i>European Journal of Internal Medicine</i> , 2020, 76, 43-49.	1.0	349
3	GM-CSF blockade with mavrimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study. <i>Lancet Rheumatology</i> , The, 2020, 2, e465-e473.	2.2	173
4	Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study. <i>Lancet Rheumatology</i> , The, 2021, 3, e253-e261.	2.2	140
5	Erdheim-Chester disease. <i>European Journal of Internal Medicine</i> , 2015, 26, 223-229.	1.0	123
6	Impact of COVID-19 pandemic on patients with large-vessel vasculitis in Italy: a monocentric survey. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1252-1253.	0.5	51
7	FRI0506...EFFICACY AND SAFETY OF CANAKINUMAB IN ADULT-ONSET STILLâ€™S DISEASE: A SINGLE-CENTER REAL-LIFE EXPERIENCE. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 851.1-852.	0.5	43
8	Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series. <i>European Journal of Internal Medicine</i> , 2021, 93, 87-94.	1.0	41
9	Treating Heart Inflammation With Interleukin-1 Blockade in a Case of Erdheimâ€™Chester Disease. <i>Frontiers in Immunology</i> , 2018, 9, 1233.	2.2	37
10	Anti-PD1 therapy-associated cutaneous leucocytoclastic vasculitis: A case series. <i>European Journal of Internal Medicine</i> , 2018, 57, e11-e12.	1.0	36
11	Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation. <i>Frontiers in Immunology</i> , 2021, 12, 675678.	2.2	35
12	Subclinical giant cell arteritis in new onset polymyalgia rheumatica A systematic review and meta-analysis of individual patient data. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 55, 152017.	1.6	32
13	Efficacy of canakinumab as first-line biologic agent in adult-onset Stillâ€™s disease. <i>Arthritis Research and Therapy</i> , 2019, 21, 54.	1.6	31
14	Potential acceptance of COVID-19 vaccine in rheumatological patients: a monocentric comparative survey. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 816-817.	0.5	30
15	Tocilizumab in patients with multisystem Erdheimâ€™Chester disease. <i>Oncolmmunology</i> , 2017, 6, e1318237.	2.1	29
16	Probability-based algorithm using ultrasound and additional tests for suspected GCA in a fast-track clinic. <i>RMD Open</i> , 2020, 6, e001297.	1.8	29
17	Repurposing of Biologic and Targeted Synthetic Anti-Rheumatic Drugs in COVID-19 and Hyper-Inflammation: A Comprehensive Review of Available and Emerging Evidence at the Peak of the Pandemic. <i>Frontiers in Pharmacology</i> , 2020, 11, 598308.	1.6	29
18	Efficacy and safety of TNF-Î± antagonists and tocilizumab in Takayasu arteritis: multicentre retrospective study of 209 patients. <i>Rheumatology</i> , 2022, 61, 1376-1384.	0.9	26

#	ARTICLE	IF	CITATIONS
19	Interleukin-1 and Systemic Sclerosis: Getting to the Heart of Cardiac Involvement. <i>Frontiers in Immunology</i> , 2021, 12, 653950.	2.2	26
20	Efficacy and safety of tocilizumab in giant cell arteritis: a single centre NHS experience using imaging (ultrasound and PET-CT) as a diagnostic and monitoring tool. <i>RMD Open</i> , 2020, 6, e001417.	1.8	24
21	Drug retention and discontinuation reasons between seven biologics in patients with Takayasu arteritis. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 509-514.	1.6	24
22	Efficacy and safety of apremilast for Behçet's syndrome: a real-life single-centre Italian experience. <i>Rheumatology</i> , 2020, 59, 171-175.	0.9	23
23	Development and validation of SCOPE score: A clinical score to predict COVID-19 pneumonia progression to severe respiratory failure. <i>Cell Reports Medicine</i> , 2022, 3, 100560.	3.3	23
24	Gender differences in clinical presentation and vascular pattern in patients with Takayasu arteritis. <i>Scandinavian Journal of Rheumatology</i> , 2019, 48, 482-490.	0.6	22
25	Successful use of cyclosporin A and interleukin-1 blocker combination therapy in VEXAS syndrome: a single-center case series. <i>Arthritis and Rheumatology</i> , 2022, 74, 1302-1303.	2.9	21
26	Prevalence of Takayasu arteritis in young women with acute ischemic heart disease. <i>International Journal of Cardiology</i> , 2018, 252, 21-23.	0.8	19
27	Living with fibromyalgia during the COVID-19 pandemic: mixed effects of prolonged lockdown on the well-being of patients. <i>Rheumatology</i> , 2021, 60, 465-467.	0.9	18
28	The fibrogenic chemokine CCL18 is associated with disease severity in Erdheim-Chester disease. <i>OncImmunology</i> , 2018, 7, e1440929.	2.1	17
29	Ultrasonographic Halo Score in giant cell arteritis: association with intimal hyperplasia and ischaemic sight loss. <i>Rheumatology</i> , 2021, 60, 4361-4366.	0.9	15
30	Efficacy and improved tolerability of combination therapy with interleukin-1 blockade and MAPK pathway inhibitors for the treatment of Erdheim-Chester disease. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e11-e11.	0.5	15
31	Disease stratification in giant cell arteritis to reduce relapses and prevent long-term vascular damage. <i>Lancet Rheumatology</i> , The, 2021, 3, e886-e895.	2.2	15
32	Drug retention rates of biological agents in adult onset Still's disease. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1-6.	1.6	14
33	Efficacy and Safety of Methotrexate for the Treatment of Autoimmune Virus-Negative Myocarditis. <i>Journal of Clinical Rheumatology</i> , 2021, 27, e143-e146.	0.5	13
34	Presenting features and outcomes of cranial-limited and large-vessel giant cell arteritis: a retrospective cohort study. <i>Scandinavian Journal of Rheumatology</i> , 2022, 51, 59-66.	0.6	10
35	Oncogene-induced maladaptive activation of trained immunity in the pathogenesis and treatment of Erdheim-Chester disease. <i>Blood</i> , 2021, 138, 1554-1569.	0.6	10
36	A Prospective Observational Study on the Efficacy and Safety of Infliximab-Biosimilar (CT-P13) in Patients With Takayasu Arteritis (TAKASIM). <i>Frontiers in Medicine</i> , 2021, 8, 723506.	1.2	10

#	ARTICLE	IF	CITATIONS
37	Looking ahead: giant-cell arteritis in 10 years time. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022, 14, 1759720X2210963.	1.2	10
38	Large-vessel Vasculitis Affecting the Aorta and its Branches in Relapsing Polychondritis: Case Series and Systematic Review of the Literature. <i>Journal of Rheumatology</i> , 2020, 47, 1780-1784.	1.0	9
39	Long-Term Efficacy and Safety of Leflunomide in Large-Vessel Giant Cell Arteritis. <i>Journal of Clinical Rheumatology</i> , 2022, 28, e297-e300.	0.5	9
40	Failure of first anti-TNF agent in Takayasu's arteritis: to switch or to swap?. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 129-134.	0.4	9
41	Response to: "Correspondence on "Impact of COVID-19 pandemic on patients with large-vessels vasculitis in Italy: a monocentric survey" by Comarmond et al". <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e31-e31.	0.5	8
42	Tocilizumab for the Treatment of Myocardial Inflammation Shown by Cardiac Magnetic Resonance. <i>Journal of Clinical Rheumatology</i> , 2019, Publish Ahead of Print, .	0.5	7
43	One year later: The case of tocilizumab in COVID-19. <i>European Journal of Internal Medicine</i> , 2022, 95, 5-6.	1.0	7
44	Effectiveness and safety of infliximab dose escalation in patients with refractory Takayasu arteritis: A real-life experience from a monocentric cohort. <i>Modern Rheumatology</i> , 2022, 32, 406-412.	0.9	7
45	"Multimodal Chorioretinal Imaging in Erdheim-Chester Disease". <i>Clinical Ophthalmology</i> , 2020, Volume 14, 581-588.	0.9	6
46	Autoantibody positivity predicts severity of rheumatic immune-related adverse events to immune-checkpoint inhibitors. <i>European Journal of Internal Medicine</i> , 2022, 103, 95-99.	1.0	6
47	The target on B cells in Systemic Sclerosis: a "midsummer dream" to extinguish inflammation and prevent early disease progression to fibrosis. <i>Clinical Rheumatology</i> , 2021, 40, 2529-2533.	1.0	5
48	Interleukin-1 and interleukin-6 inhibition in patients with COVID-19 and hyperinflammation " Authors' reply. <i>Lancet Rheumatology</i> , The, 2021, 3, e248-e249.	2.2	4
49	Current and innovative therapeutic strategies for the treatment of giant cell arteritis. <i>Expert Opinion on Orphan Drugs</i> , 2021, 9, 161-173.	0.5	4
50	Spontaneous Coronary-Artery Dissection. <i>New England Journal of Medicine</i> , 2021, 384, 1077-1078.	13.9	3
51	AB0466 "EFFICACY AND SAFETY OF INFliximab-BIOSIMILAR IN TAKAYASU ARTERITIS (TAKASIM): A MONOCENTRIC, OBSERVATIONAL, PROSPECTIVE, OPEN-LABEL STUDY. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1531.2-1531.	0.5	3
52	Primary heart involvement in systemic sclerosis, from conventional to innovative targeted therapeutic strategies. <i>Journal of Scleroderma and Related Disorders</i> , 2022, 7, 179-188.	1.0	3
53	AB0621 "GENDER DIFFERENCES IN CLINICAL PRESENTATION AND VASCULAR PATTERN IN PATIENTS WITH TAKAYASU ARTERITIS. , 2019, , .		2
54	POS1341 "TOCILIZUMAB FOR THE TREATMENT OF IMMUNE-RELATED ADVERSE EVENTS TO IMMUNE CHECKPOINT INHIBITORS: A CASE SERIES. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 953.1-953.	0.5	2

#	ARTICLE	IF	CITATIONS
55	Myocarditis as a manifestation of Erdheim-Chester Disease: successful use of anti-IL1 and BRAF inhibitor combination therapy. <i>Scandinavian Journal of Rheumatology</i> , 2022, 51, 243-245.	0.6	2
56	AB0631-Hypersensitivity to Rituximab: A Rapid and Simplified Desensitization Protocol for Patients with Anca-Associated Vasculitis and Other Autoimmune Disorders. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1110.1-1110.	0.5	1
57	An enlightening scan. <i>European Journal of Internal Medicine</i> , 2015, 26, 68-69.	1.0	1
58	Bilateral temporal arteries 18F-FDG PET uptake in giant cell arteritis. <i>Rheumatology</i> , 2020, 59, 343-343.	0.9	1
59	Clinically isolated aortitis successfully treated with methotrexate monotherapy. <i>Rheumatology</i> , 2020, 59, e54-e56.	0.9	1
60	Canakinumab injection for the treatment of active Still's disease, including adult-onset Still's disease. <i>Expert Opinion on Orphan Drugs</i> , 2021, 9, 77-86.	0.5	1
61	Clinical and dermoscopic description of accelerated nodulosis after tocilizumab treatment for an isolated aortitis with coronary involvement. <i>International Journal of Dermatology</i> , 2021, 60, e359-e361.	0.5	1
62	POS0337-SOUTHEND PRE-TEST PROBABILITY SCORE AND HALO SCORE AS MARKERS FOR DIAGNOSIS AND MONITORING OF GCA: EARLY RESULTS FROM THE PROSPECTIVE HAS-GCA STUDY. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 396-397.	0.5	1
63	AB0361-EFFECTIVENESS AND SAFETY OF INFLIXIMAB DOSE ESCALATION IN PATIENTS WITH REFRACTORY TAKAYASU ARTERITIS: A REAL-LIFE EXPERIENCE FROM A MONOCENTRIC COHORT. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1206.1-1206.	0.5	1
64	FRI0478-SEROLOGICAL AUTOIMMUNITY IN PATIENTS WITH RHEUMATIC IMMUNE-RELATED ADVERSE EVENTS: CORRELATION WITH SEVERITY AND TREATMENT. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 836.2-836.	0.5	1
65	Efficacy and Safety of Methotrexate for the Treatment of Autoimmune Virus-Negative Myocarditis. <i>Journal of Clinical Rheumatology</i> , 2018, , 1.	0.5	1
66	Failure of first anti-TNF agent in Takayasu's arteritis: to switch or to swap?. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 129, 129-134.	0.4	1
67	Patients' experience and tolerability with canakinumab and anakinra for the treatment of adult-onset Still's disease.. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.4	1
68	THU0363-Pilot Study of TOCILIZUMAB in Patients with Erdheim-Chester Disease. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 308.1-308.	0.5	0
69	THU0372-The Role of Echocardiography and Cardiac MRI in Erdheim-Chester Disease. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 311.1-311.	0.5	0
70	FRI0325-Prevalence of takayasu arteritis in young women with acute ischemic heart disease. , 2017, , .		0
71	AB0647-Takayasu's arteritis in italy: clinical presentation, diagnostic delay and vascular pattern. , 2018, , .		0
72	357.EFFICACY AND SAFETY OF TOCILIZUMAB IN GIANT CELL ARTERITIS: A MONOCENTRIC REAL-LIFE EXPERIENCE. <i>Rheumatology</i> , 2019, 58, .	0.9	0

#	ARTICLE	IF	CITATIONS
73	168.â€fGENDER DIFFERENCES IN CLINICAL PRESENTATION AND VASCULAR PATTERN IN PATIENTS WITH TAKAYASUâ€™S ARTERITIS. Rheumatology, 2019, 58, .	0.9	0
74	273.â€fTAKAYASUâ€™S ARTERITIS: BEYOND THE VESSELS. Rheumatology, 2019, 58, .	0.9	0
75	288.â€fDRUG RETENTION AND DISCONTINUATION REASONS BETWEEN EIGHT BIOLOGICS IN PATIENTS WITH TAKAYASUâ€™S ARTERITIS: A SINGLE-CENTER EXPERIENCE. Rheumatology, 2019, 58, .	0.9	0
76	FRI0585â€™...EFFICACY OF CANAKINUMAB AS FIRST-LINE BIOLOGIC AGENT IN ADULT-ONSET STILLâ€™S DISEASE. , 2019, , .		0
77	AB0613â€™...PRESENTATION OF TAKAYASU ARTERITIS ACCORDING TO THE AGE OF ONSET IN A MONOCENTRIC ITALIAN COHORT. , 2019, , .		0
78	AB0620â€™...EFFICACY AND SAFETY OF TOCILIZUMAB IN GIANT CELL ARTERITIS: A MONOCENTRIC REAL-LIFE EXPERIENCE. , 2019, , .		0
79	THU0293â€™...DRUG RETENTION AND DISCONTINUATION REASONS BETWEEN SEVEN BIOLOGICS IN PATIENTS WITH TAKAYASUâ€™S ARTERITIS: A SINGLE-CENTER EXPERIENCE. , 2019, , .		0
80	THU0319â€™...TAKAYASUâ€™S ARTERITIS: BEYOND THE VESSELS. , 2019, , .		0
81	POS1347â€™...IMPACT OF CANAKINUMAB AND ANAKINRA ON PATIENT-REPORTED OUTCOMES IN ADULT-ONSET STILLâ€™S DISEASE PATIENTS. Annals of the Rheumatic Diseases, 2021, 80, 955.3-956.	0.5	0
82	POS1336â€™...RETROPERITONEAL FIBROSIS IN ERDHEIM-CHESTER DISEASE HAS UNIQUE PRESENTING AND PROGNOSTIC FEATURES: A SINGLE CENTRE RETROSPECTIVE COMPARATIVE COHORT STUDY. Annals of the Rheumatic Diseases, 2021, 80, 950-951.	0.5	0
83	POS0806â€™...FINDINGS CONSISTENT WITH SUBCLINICAL VASCULITIS IN PATIENTS WITH NEW ONSET POLYMYALGIA: A SYSTEMATIC LITERATURE REVIEW AND A META-ANALYSIS OF COHORT DATA. Annals of the Rheumatic Diseases, 2021, 80, 655.2-656.	0.5	0
84	Myocardial infarction in giant cell arteritis: It is all a matter of balance.. European Journal of Internal Medicine, 2021, 89, 1-2.	1.0	0
85	Response to â€Correspondence on â€Impact of COVID-19 pandemic on patients with large-vessels vasculitis in Italy: a monocentric surveyâ€™â€™ by Montero et al. Annals of the Rheumatic Diseases, 2021, , annrhumdis-2021-220959.	0.5	0
86	SAT0517â€™...Gender differences influences clinical presentation and vascular pattern in patients with takayasu arteritis: an italian monocentric study. , 2018, , .		0
87	SAT0521â€™...A prospective observational study on the safety and efficacy of infliximab-biosimilar in patients with takayasuâ€™s arteritis (TAKASIM): preliminary data. , 2018, , .		0
88	FRI0191â€™...CRANIAL-LIMITED AND LARGE-VESSEL GIANT CELL ARTERITIS: PRESENTING FEATURES AND OUTCOME. Annals of the Rheumatic Diseases, 2020, 79, 678.3-679.	0.5	0
89	FRI0212â€™...THE ROLE OF AGE ON THE CLINICAL PRESENTATION AND RELAPSE RATES IN A LARGE COHORT OF 720 PATIENTS WITH GIANT CELL ARTERITIS. Annals of the Rheumatic Diseases, 2020, 79, 689.1-690.	0.5	0
90	FRI0484â€™...SAFETY PROFILE, CLINICAL AND RADIOLOGICAL EFFICACY OF ANAKINRA, TARGETED AND COMBINED TREATMENT IN ERDHEIM-CHESTER DISEASE. Annals of the Rheumatic Diseases, 2020, 79, 839.1-840.	0.5	0

#	ARTICLE	IF	CITATIONS
91	FRI0214â€¦PERSISTENT LOW-GRADE FDG-PET VASCULAR INFLAMMATION IN REMITTED LVV-GCA PATIENTS IS ASSOCIATED TO A SIGNIFICANT HIGH RISK OF RELAPSE. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 690.2-691.	0.5	0
92	AB0534â€¦EFFICACY OF TOCILIZUMAB IN LARGE-VESSEL GIANT CELL ARTERITIS: A SINGLE-CENTER REAL-LIFE EXPERIENCE. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1563.1-1564.	0.5	0
93	SAT0519â€¦DRUG RETENTION RATES OF BIOLOGICAL AGENTS IN ADULT ONSET STILLâ€™S DISEASE IN THE PRE-CANAKINUMAB ERA. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1215-1216.	0.5	0
94	THU0298â€¦SWITCH OR SWAP STRATEGY IN TAKAYASU ARTERITIS PATIENTS FAILING TNFA INHIBITORS?. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 377-377.	0.5	0
95	Comment on: Diagnostic accuracy of ultrasound for detecting large-vessel giant cell arteritis using FDG PET/CT as the reference. <i>Rheumatology</i> , 2021, 60, e66-e66.	0.9	0
96	Subclinical Giant Cell Arteritis in New Onset Polymyalgia Rheumatica: A Systematic Review and Meta-Analysis of Individual Patient Data. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
97	Patients' experience and tolerability with canakinumab and anakinra for the treatment of adult-onset Still's disease.. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.4	0